https://www.businesswire.com/news/home/20181115006053/en/

HAYWARD, Calif.--(BUSINESS WIRE)--Nov 15, 2018--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on November 15, 2018.

The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual’s entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).